DAFNA Capital Management as of Dec. 31, 2014
Portfolio Holdings for DAFNA Capital Management
DAFNA Capital Management holds 62 positions in its portfolio as reported in the December 2014 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Pharmacyclics | 10.7 | $14M | 111k | 122.26 | |
| AtriCure (ATRC) | 10.4 | $13M | 661k | 19.96 | |
| Auspex Pharmaceuticals | 5.6 | $7.1M | 136k | 52.48 | |
| NxStage Medical | 5.4 | $6.9M | 384k | 17.93 | |
| Discovery Laboratories Com New | 5.2 | $6.6M | 5.7M | 1.16 | |
| Insulet Corporation (PODD) | 4.0 | $5.0M | 109k | 46.06 | |
| Novadaq Technologies | 3.5 | $4.4M | 264k | 16.62 | |
| Ocera Therapeutics | 3.2 | $4.0M | 635k | 6.37 | |
| Aerie Pharmaceuticals | 3.1 | $3.9M | 132k | 29.19 | |
| Derma Sciences Com Par $.01 | 2.8 | $3.6M | 385k | 9.31 | |
| Intercept Pharmaceuticals In | 2.7 | $3.4M | 22k | 155.98 | |
| Cti Biopharma | 2.7 | $3.4M | 1.4M | 2.36 | |
| Protalix Biotherapeutics Note 4.500% 9/1 (Principal) | 2.5 | $3.2M | 4.0M | 0.80 | |
| Insulet Corp Note 2.000% 6/1 (Principal) | 2.3 | $2.9M | 2.4M | 1.19 | |
| Protalix BioTherapeutics | 2.0 | $2.5M | 1.4M | 1.84 | |
| Achillion Pharmaceuticals | 1.9 | $2.4M | 198k | 12.25 | |
| Biotelemetry | 1.9 | $2.4M | 236k | 10.03 | |
| Stereotaxis Com New (STXS) | 1.6 | $2.0M | 1.4M | 1.48 | |
| BioCryst Pharmaceuticals (BCRX) | 1.6 | $2.0M | 167k | 12.16 | |
| Masimo Corporation (MASI) | 1.4 | $1.8M | 68k | 26.34 | |
| Rigel Pharmaceuticals Com New | 1.3 | $1.7M | 749k | 2.27 | |
| Threshold Pharmaceuticals Com New | 1.3 | $1.7M | 531k | 3.18 | |
| Trevena | 1.3 | $1.7M | 280k | 5.98 | |
| Spectranetics Corporation | 1.2 | $1.5M | 42k | 34.58 | |
| Neothetics, Inc. Cmn | 1.1 | $1.4M | 187k | 7.48 | |
| Clovis Oncology | 1.1 | $1.3M | 24k | 55.98 | |
| BioSpecifics Technologies | 1.0 | $1.3M | 34k | 38.61 | |
| Nuvasive Note 2.750% 7/0 (Principal) | 1.0 | $1.3M | 1.0M | 1.29 | |
| Targacept | 1.0 | $1.2M | 465k | 2.63 | |
| Venaxis | 0.9 | $1.2M | 658k | 1.77 | |
| Bluebird Bio (BLUE) | 0.9 | $1.1M | 13k | 91.76 | |
| Cynapsus Therapeutics | 0.8 | $1.0M | 949k | 1.10 | |
| Cardica | 0.8 | $1.0M | 1.5M | 0.70 | |
| Uroplasty Com New | 0.8 | $1.0M | 486k | 2.06 | |
| Johnson & Johnson (JNJ) | 0.8 | $983k | 9.4k | 104.57 | |
| Cytrx Corp Com Par $.001 | 0.8 | $949k | 346k | 2.74 | |
| Cutera (CUTR) | 0.7 | $947k | 89k | 10.68 | |
| Galmed Pharmaceuticals SHS | 0.7 | $917k | 158k | 5.80 | |
| Encision | 0.7 | $882k | 1.1M | 0.83 | |
| XenoPort | 0.7 | $861k | 98k | 8.77 | |
| Syneron Medical Ord Shs | 0.7 | $849k | 91k | 9.34 | |
| Exactech | 0.6 | $746k | 32k | 23.58 | |
| Affimed Therapeutics Bv Com Added | 0.6 | $744k | 120k | 6.20 | |
| Caredx Com Added (CDNA) | 0.5 | $633k | 87k | 7.25 | |
| Intellipharmaceuticsintl Inc C | 0.5 | $631k | 279k | 2.26 | |
| Uniqure B.v. NV SHS (QURE) | 0.5 | $587k | 40k | 14.80 | |
| RTI Biologics | 0.4 | $447k | 86k | 5.20 | |
| Genvec Com New | 0.3 | $416k | 200k | 2.08 | |
| Second Sight Med Prods | 0.3 | $408k | 40k | 10.25 | |
| Lpath Com New | 0.3 | $344k | 122k | 2.82 | |
| Fate Therapeutics (FATE) | 0.2 | $297k | 59k | 5.02 | |
| Lumenis SHS CL B | 0.2 | $290k | 31k | 9.33 | |
| Probiodrug | 0.2 | $244k | 11k | 23.24 | |
| Cynapsus Therapeutics | 0.2 | $240k | 281k | 0.85 | |
| Nanosphere | 0.2 | $235k | 600k | 0.39 | |
| Essa Pharma PFD | 0.2 | $222k | 250k | 0.89 | |
| Celsus Therapeutics Sponsored Adr Ne | 0.2 | $211k | 44k | 4.81 | |
| Biolife Solutions Com New (BLFS) | 0.2 | $191k | 116k | 1.64 | |
| Proteon Therapeutics | 0.1 | $132k | 13k | 10.39 | |
| Chembio Diagnostics Com New | 0.1 | $103k | 26k | 3.92 | |
| Globeimmune Com Added (GBIM) | 0.1 | $83k | 11k | 7.58 | |
| Inspiremd Com New | 0.0 | $50k | 64k | 0.78 |
